title: [The expression and functional study of miR-181a in pediatric acute lymphoblastic leukemia].
abstract: OBJECTIVE
  To investigate the expression of miR-181a in bone marrow (BM) samples of pediatric acute lymphoblastic leukemia (ALL) and explore the mechanism of miR-181a on ALL cell line CCRF-CEM and drug resistance cell line CEM-C1.
  
  
  METHODS
  BM samples were obtained from 18 patients where matched samples at initial diagnosis and first BM relapse or complete remission were available. BM samples and cord blood samples (normal controls) were used to confirm the differential expression of miRNA-181a by quantitative real-time polymerase chain reaction (qRT-PCR). The expressions of miR-181a in both CCRF-CEM and its mutidrug-resistant counterpart CEM-C1 cells were also detected. Then, CCK-8 assay was performed to quantify the effects of miR-181a on CEM-C1 and CCRF-CEM cells growth and viability.
  
  
  RESULTS
  Up-regulated miR-181a with higher fold changes in both initial diagnosis (4.84 ± 2.71, 7.58 ± 2.50) and relapsed samples (6.53 ± 2.20) compared to normal controls (1.41 ± 0.53) (P=0.017, 0.000, 0.001, respectively) were observed, whereas the miR-181a expression in the samples of CR (1.35 ± 0.35) compared to normal control showed no significant difference (P=0.863). The miR-181a expression level was higher in CEM-C1 cells (-4.39 ± 0.08) than of in CCRF-CEM cells (-2.32 ± 0.03) (P=0.000). CCK-8 assay revealed that suppression of miR-181a in CEM-C1 cells by transfecting the specific inhibitor of miR-181a led to significantly higher cellular proliferation inhibition rate than negative control cells (P<0.05), IC50 were 30.61 ng/ml and 2 255.00 ng/ml with RI as 73.67. While increased miR-181a in CCRF-CEM cells led to significantly lower CPIR than negative control cells (P<0.01), IC50 were 126.60 ng/ml and 1.34 ng/ml with RI as 94.26.
  
  
  CONCLUSIONS
  Upregulation of miR-181a might play an important role in the development of drug resistance in CEM-C1 cells, and knockdown of miR-181a could sensitize CEM-C1 cells to camptothecin; Meanwhile increased expression of miR-181a could promote CCRF-CEM drug resistance. These results suggested that suppression of miR-181a expression might provide a promising therapeutic in drug resistance of leukaemia.
authors: Birth Cohort Study Lab, Guangzhou Women and Children Medical Center, Guangzhou Medical University, Guangzhou 510623, China.
authors: Wang
authors: W
authors: Liao
authors: Birth Cohort Study Lab, Guangzhou Women and Children Medical Center, Guangzhou Medical University, Guangzhou 510623, China.
authors: Xiaodan
authors: X
authors: Liu
authors: Birth Cohort Study Lab, Guangzhou Women and Children Medical Center, Guangzhou Medical University, Guangzhou 510623, China.
authors: Hongxia
authors: H
authors: Peng
authors: Birth Cohort Study Lab, Guangzhou Women and Children Medical Center, Guangzhou Medical University, Guangzhou 510623, China.
authors: Ling
authors: L
authors: Xu
mesh_terms: D002648:Child; D006801:Humans; D035683:MicroRNAs; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma; D060888:Real-Time Polymerase Chain Reaction; D015854:Up-Regulation
chemical_list: D035683:MicroRNAs
references: Acta Biochim Biophys Sin (Shanghai). 2012 Mar;44(3):269-77
references: 22285729
references: Biochem Biophys Res Commun. 2011 Jan 28;404(4):896-902
references: 21167132
references: Blood. 2010 Dec 9;116(24):5228-36
references: 20841506
references: Oncogene. 2007 Apr 26;26(19):2799-803
references: 17072344
references: Int J Hematol. 2000 Oct;72(3):290-7
references: 11185984
references: Oncogene. 2013 Jun 20;32(25):3019-27
references: 22847611
references: Oncol Rep. 2013 Feb;29(2):555-62
references: 23229111
references: Blood. 2008 Jun 15;111(12):5515-23
references: 18334672
references: Blood. 2010 Sep 30;116(13):2395-401
references: 20558617
references: Int J Oncol. 2011 Apr;38(4):955-62
references: 21271219
references: Microvasc Res. 2009 Dec;78(3):393-404
references: 19595696
references: Curr Opin Genet Dev. 2005 Apr;15(2):200-5
references: 15797203
references: Int J Cancer. 2008 Jul 15;123(2):372-379
references: 18449891
references: J Cancer Res Clin Oncol. 2012 Apr;138(4):595-602
references: 22209977
references: PLoS One. 2009 Nov 13;4(11):e7826
references: 19915715